EVAX Evaxion Biotech A/S Total Debt to Capital
Evaxion Biotech A/S (EVAX) is actively developing personalized oncology treatments by utilizing the PIONEER system to analyze specific mutations. Business growth is driven by partnerships with pharmaceutical behemoths and the success of clinical trials. The linear price action on the GURU.Markets chart shows that the individual debt-to-equity ratio is 0.74. Due to the technological superiority of EDIVAX, the company possesses significant pricing power in setting the cost of its products.
%20-%20Total%20Debt%20to%20Capital%20Coefficient&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_EVAX_-_Evaxion-Biotech-AS_-_Total-Debt-to-Capital-Coefficient "EVAX Evaxion Biotech Corp Total Debt to Capital (07/04/2022 - 10/29/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Evaxion Biotech AS (EVAX)
This ratio measures financial leverage by comparing total liabilities to net assets to determine the business's degree of dependence on debt financing. By analyzing the proportion of total debt to equity, an investor can assess the resilience of Evaxion Biotech A/S (EVAX) to geopolitical risks and trade restrictions, which could limit revenue from international software and complicate debt servicing.